Highlights Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Market Closed - Nyse Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
15.07 ^USD	+0.94%		-6.51%	-21.10%

May. 16	Transcript : Arcus Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM
May. 08	Transcript : Arcus Biosciences, Inc., Q1 2024 Earnings Call, May 08, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M	May. 08	MT
Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M	May. 08	MT
Arcus Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Earnings Flash (RCUS) ARCUS BIOSCIENCES Reports Q4 Revenue $31M	Feb. 21	MT
Arcus Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Gilead and Arcus Announce Amended Collaboration Agreement	Jan. 31	CI
Global markets live: WPP UPS GM, Super Micro Computer, Microsoft...	Jan. 30
North American Morning Briefing : Microsoft Kicks Off Big Tech Bonanza	Jan. 30	DJ
Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%	Jan. 29	RE
Arcus Biosciences, Inc. Announces Data from A Phase 1B Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naive Metastatic Pancreatic Cancer	Jan. 16	CI
Exelixis, Inc. and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with Ab521 in Patients with Advanced Renal Cell Carcinoma	Dec. 04	CI
Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q3 Revenue $32M, vs. Street Est of $27.6M	Nov. 07	MT
Arcus Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers	Nov. 06	CI
Arcus Biosciences' Q2 Net Loss Widens, Revenue Rises	23-08-07	MT
Arcus Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Earnings Flash (RCUS) ARCUS BIOSCIENCES Reports Q2 Revenue $29M, vs. Street Est of $31.8M	23-08-07	MT
Gilead Sciences Ups Stake in Arcus Biosciences to 35%	23-07-06	MT
Arcus Biosciences, Inc. Provides Updated Results from an Interim Analysis of ARC-7	23-06-05	CI
Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study	23-06-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Highlights

Filters